Ekso Bionics (EKSO) Projected to Post Quarterly Earnings on Monday

Ekso Bionics (NASDAQ:EKSO) is anticipated to release its Q4 2025 results before the market opens on Monday, March 2nd. Analysts expect Ekso Bionics to post earnings of ($0.08) per share and revenue of $5.0260 million for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Wednesday, March 4, 2026 at 4:00 PM ET.

Ekso Bionics Trading Down 9.1%

Shares of EKSO opened at $11.18 on Monday. The stock has a market capitalization of $29.29 million, a PE ratio of -1.97 and a beta of 0.80. The company’s fifty day moving average is $8.30 and its 200 day moving average is $5.78. The company has a debt-to-equity ratio of 0.11, a quick ratio of 1.09 and a current ratio of 1.66. Ekso Bionics has a fifty-two week low of $2.73 and a fifty-two week high of $13.27.

Insider Transactions at Ekso Bionics

In other Ekso Bionics news, major shareholder Daniel Asher bought 15,540 shares of the company’s stock in a transaction on Thursday, February 19th. The stock was acquired at an average price of $12.30 per share, for a total transaction of $191,142.00. Following the completion of the transaction, the insider directly owned 270,432 shares of the company’s stock, valued at approximately $3,326,313.60. This represents a 6.10% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 6.10% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Ekso Bionics

A number of institutional investors and hedge funds have recently modified their holdings of EKSO. Citadel Advisors LLC bought a new position in Ekso Bionics in the 3rd quarter valued at $198,000. Shay Capital LLC bought a new position in shares of Ekso Bionics during the 3rd quarter worth approximately $67,000. Virtu Financial LLC purchased a new stake in Ekso Bionics during the third quarter valued at approximately $57,000. Finally, Geode Capital Management LLC boosted its stake in Ekso Bionics by 68.9% in the fourth quarter. Geode Capital Management LLC now owns 25,212 shares of the company’s stock valued at $218,000 after acquiring an additional 10,281 shares in the last quarter. 6.42% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

EKSO has been the topic of several recent research reports. Wall Street Zen upgraded shares of Ekso Bionics to a “hold” rating in a research report on Saturday, December 13th. HC Wainwright downgraded Ekso Bionics from a “buy” rating to a “neutral” rating in a research report on Wednesday, December 31st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Ekso Bionics in a report on Monday, December 22nd. One analyst has rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $10.50.

About Ekso Bionics

Ekso Bionics Holdings, Inc (NASDAQ:EKSO) is a leading developer of wearable bionic exoskeletons designed to enhance human mobility and strength. Headquartered in Richmond, California, the company was founded in 2005 (originally as Berkeley Bionics) and completed its initial public offering in 2014. Its patented robotic systems support both rehabilitation and industrial applications by providing powered, adjustable assistance for a range of movement tasks.

In the medical sector, Ekso Bionics offers externally worn exoskeletons such as the EksoNR and EksoGT, which assist patients recovering from stroke, spinal cord injury or other neurological conditions.